ALS research is producing real, measured signals from regenerative medicine.
ALS is one of the hardest problems in neurology, which makes the progress here worth reading carefully. Regenerative medicine has moved from laboratory promise to controlled human trials, and some of those trials have produced measurable signals in function and survival, enough that one program has earned conditional approval in a major regulated market.
Here is what the research shows across stem cells, Muse cells, and exosomes, and how a candidacy review determines whether it fits your case.
Aurenza does not claim that regenerative medicine treats, cures, slows, or reverses ALS. Individual results vary.
Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.
What the Research Shows
The most encouraging controlled data comes from repeated intrathecal delivery of mesenchymal stem cells. A randomized controlled trial in Annals of Neurology (2018) found that treated patients declined more slowly on the ALS functional scale than controls, a difference of roughly 3 points at four and six months. That result supported South Korea's conditional approval of the therapy, one of the few times a regulator has cleared a cell therapy in this disease.
The survival data points the same direction. A long-term surveillance study in Frontiers in Aging Neuroscience (2023) followed 157 treated patients against matched controls and found lower mortality with treatment, with the strongest effect in patients who received repeated dosing. Earlier cell programs showed the biology is active: in a phase 2 study in Neurology (2019), treated patients showed measurable changes in spinal-fluid neurotrophic and inflammatory markers, confirming the cells are doing something real in the nervous system.
Newer regenerative tools are entering the picture. Muse cells have reached a human phase 2 study in ALS, published in Cell Transplantation (2023), where the therapy was well tolerated and neurofilament light, a marker of nerve damage, ran lower than natural-history comparators. And MSC-derived exosomes and secretome are an actively developing direction for ALS reviewed across the recent literature, valued for delivering these cells' neuroprotective signals without the cells themselves.
What the Evidence Does and Does Not Yet Show
The honest, hopeful summary: regenerative medicine in ALS has produced a positive randomized trial, a survival signal, and a conditional approval abroad, which is genuine forward motion in a disease that resists it. At the same time, larger pivotal trials have had mixed results, including a phase 3 study of one leading program that did not meet its primary endpoint, which is exactly why individual candidacy matters so much here: the patients who appear to benefit most are earlier in their course and receive repeated dosing. Muse and exosome approaches are earlier still and are best understood as emerging. Established ALS care, including riluzole and edaravone, remains the foundation and is never replaced.
Why This Is Exactly Where a Candidacy Review Comes In
Your diagnosis, your stage, and how quickly your disease is progressing decide whether the encouraging data above describes you, because the clearest signals came from earlier-stage patients receiving repeated treatment. That is the gap between what is published and what is right for you, and it is what a candidacy review closes. Your diagnosis, current function, and standard care are reviewed by a physician panel, coordinated with your treating neurologist, so that any recommendation is matched honestly to your situation. That is where to start.
Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.
What Your Candidacy Review Covers
Your confirmed diagnosis and stage, since the strongest signals came from earlier-stage patients.
Your progression rate, which shapes what repeated regenerative treatment might realistically offer.
Your current standard care, including riluzole and edaravone, which nothing here replaces.
Your goals, assessed honestly against what the evidence supports.
Your case is reviewed by a physician panel, with neurology input, coordinated with your treating specialist.
What to Ask Any Provider
Which controlled trials support this for my stage of ALS, and what did they measure? Are you proposing stem cells, Muse cells, or an exosome approach, and how many treatments? What is being administered, at what verified cell count, and by what route? How will you coordinate with my neurologist and my standard care? What would make me a poor candidate?
The Honest Limits
Individual results cannot be predicted or guaranteed. No cell therapy is FDA approved for ALS in the United States, larger controlled trials have had mixed results, and any procedure takes place in Mexico under COFEPRIS regulation, which is not equivalent to FDA approval. Continue all prescribed ALS care under the direction of your treating specialist.
Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.
Free consultation with a care team member; many are registered nurses. No sales reps. You speak with a care team member from the first call.